Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0
Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Results of Operations and Financial Condition

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On July25, 2018, Supernus Pharmaceuticals,Inc. issued a press release announcing that it expects to report its financial results for the second quarter ended June30, 2018 after 5:00 PM ET on Tuesday, August7, 2018, and will hold a conference call and webcast on Wednesday, August8, 2018 to discuss its second quarter 2018 financial results. A copy of this press release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit to Item 2.02 hereof:

Exhibit99.1 – Press Release Dated July25, 2018.


SUPERNUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a18-17781_1ex99d1.htm EX-99.1 Exhibit 99.1     Supernus to Host Second Quarter 2018 Earnings Conference Call   ROCKVILLE,…
To view the full exhibit click here

About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.